RecruitingPhase 2NCT05199909
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
Studying Antiphospholipid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Principal Investigator
- Lei Zhang, MDChinese Academy of Medical Science and Blood Disease Hospital
- Intervention
- zanubrutinib(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (2)
- Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin Municipality, China
- Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05199909 on ClinicalTrials.govOther trials for Antiphospholipid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07372170Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS PatientsInfanta Leonor University Hospital
- RECRUITINGNANCT07163338Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)CHU de Reims
- RECRUITINGNANCT06373926Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid SyndromeCentre Hospitalier Universitaire, Amiens
- ENROLLING BY INVITATIONPHASE1NCT06723106Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)Chugai Pharmaceutical
- RECRUITINGNCT06373003Negative Antiphospholipid Syndrome: a Multicentric StudyItalian Society for Rheumatology
- RECRUITINGPHASE1NCT06371417Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)Chugai Pharmaceutical
- RECRUITINGPHASE2NCT06747312Effect of Belimumab on Antibody Titers in Primary APS PatientsRuijin Hospital
- RECRUITINGPHASE4NCT05995600Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKESeoul National University Hospital